NEW research has found that the combination of exercise and an Ozempic-like drug helps people shift weight, while maintaining bone density.
Conducted at the University of Copenhagen and Hvidovre Hospital, the study aimed to find out whether these new weight-loss drugs impact bone health, which is still largely unknown.
A concern with weight loss is that bone density loss can occur in people at the same time.
The study, published in JAMA Network Open, involved 195 obese adults, where the combination of weight loss drug and exercise maintained hip, spine, and forearm bone mineral density (BMD), despite significant weight loss.
However, GLP-1 RA alone reduced BMD at the hip and spine compared to placebo or exercise alone.
The randomised clinical trial highlights that adding exercise to a GLP-1 RA treatment, such as liraglutide, is an effective strategy for weight loss while protecting bone health.
Over a year, participants on the combined regimen saw the best results, maintaining BMD levels at key sites.
These findings emphasise balanced weight loss approaches that account for both weight reduction and bone health are crucial in managing obesity and preventing osteoporosis. JG
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Jun 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Jun 24
